Common drug-drug interactions in antifungal treatments for superficial fungal infections. (3rd April 2018)

• Record Type: Journal Article
• Authors: Gupta, Aditya K.; Versteeg, Sarah G.; Shear, Neil H.
• Is Part Of: Expert opinion on drug metabolism and toxicology. Volume 14:Number 4(2018)
• Page Start: 387
• Page End: 398
• Publication Date: 2018-04-03
• Subjects: Terbinafine -- itraconazole -- tavaborole -- efinaconazole -- antifungal agents -- drug interactions -- superficial infections; Drugs -- Toxicology -- Periodicals; Drugs -- Metabolism -- Periodicals; 615.7
• DOI: 10.1080/17425255.2018.1461834
• Languages: English
• ISSNs: 1742-5255

Abstract

ABSTRACT: Introduction : Antifungal agents can be co-administered alongside several other medications for a variety of reasons such as the presence of comorbidities. Pharmacodynamic interactions such as synergistic and antagonistic interactions could be the result of co-administered medications. Pharmacokinetic interactions could also transpire through the inhibition of metabolizing enzymes and drug transport systems, altering the absorption, metabolism and excretion of co-administered medications. Both pharmacodynamic and pharmacokinetic interactions can result in hospitalization due to serious adverse effects associated with antifungal agents, lower therapeutic doses required to achieve desired antifungal activity, and prevent antifungal resistance. Areas covered : The objective of this review is to summarize pharmacodynamic and pharmacokinetic interactions associated with common antifungal agents used to treat superficial fungal infections. Pharmacodynamic and pharmacokinetic interactions that impact the therapeutic effects of antifungal agents and drugs that are influenced by the presence of antifungal agents was the context to which these antifungal agents were addressed. Expert opinion : The potential for drug-drug interactions is minimal for topical antifungals as opposed to oral antifungals as they have minimal exposure to other co-administered medications. Developing non-lipophilic antifungals that have unique metabolizing pathways and are topical applied are suggested properties that could help limit drug-drug interactions associated with future treatments.